Related Experiment Video

Updated: Jun 3, 2025

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

453

Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy

Shasha Liu1, Qianyu Lan1, Weiling Li1

  • 1Department of General Internal Medicine, the Fourth Hospital of Shijiazhuang, Shijiazhuang, China.

Kidney & Blood Pressure Research
|January 8, 2025
PubMed

Insights

Serum platelet-activating factor (PAF) can predict hypertensive disorders complicating pregnancy (HDCP) and poor outcomes. Elevated PAF levels in early pregnancy and at diagnosis indicate increased risk for HDCP and adverse results.

Area of Science:

  • Reproductive Medicine
  • Biochemistry

Background:

  • Serum platelet-activating factor (PAF) is linked to gestational hypertension.
  • The predictive role of early pregnancy serum PAF for hypertensive disorders complicating pregnancy (HDCP) and their outcomes requires clarification.

Purpose of the Study:

  • To investigate the predictive value of serum PAF in early pregnancy for the occurrence and outcomes of HDCP.
  • To assess the correlation between serum PAF levels and blood pressure in HDCP patients.

Main Methods:

  • Serum PAF levels were quantified using enzyme-linked immunosorbent assay.
  • Receiver operating characteristic (ROC) curve analysis evaluated the predictive accuracy of serum PAF for HDCP occurrence and outcomes.
  • Spearman analysis assessed the correlation between serum PAF and blood pressure.

Main Results:

  • Serum PAF levels were significantly higher in HDCP patients compared to normal pregnancies.
  • Elevated serum PAF levels at early pregnancy and diagnosis correlated with increased HDCP severity and poor outcomes.
  • Serum PAF demonstrated predictive capability for both HDCP occurrence and adverse outcomes.

Conclusions:

  • Serum PAF is a valuable predictor for the occurrence and outcomes of HDCP.
  • Measurements of serum PAF in early pregnancy and at diagnosis can effectively identify patients at risk for HDCP and poor outcomes.
Abstract

Keywords:
Hypertensive disorders complicating pregnancyOccurrencePlatelet-activating factorPoor outcomePreeclampsia

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

167
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

775

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.8K